Ads
related to: xgeva vs zometa multiple myeloma cancersidekickbird.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [31] under the brand name Prolia, [32] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [33] Denosumab is the first RANKL inhibitor to be approved by the FDA. [31]
Zoledronic acid, also known as zoledronate and sold under the brand name Zometa among others, [7] by Novartis among others, is a medication used to treat a number of bone diseases. [3] These include osteoporosis , high blood calcium due to cancer , bone breakdown due to cancer, Paget's disease of bone [ 3 ] and Duchenne muscular dystrophy (DMD).
Multiple myeloma is the second-most prevalent blood cancer (10%) after non-Hodgkin's lymphoma. [154] It represents about 1.8% of all new cancers and 2.1% of all cancer deaths. [7] Multiple myeloma affects slightly more men than women.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
This effect applies in myeloma and lymphoid leukemias, lymphoma, multiple myeloma and possibly breast cancer. [3] It is closely linked with graft-versus-host disease (GvHD), as the underlying principle of alloimmunity is the same. CD4+CD25+ regulatory T cells (Treg) can be used to suppress GvHD without loss of beneficial GvT effect. [4]
The chemical structure of Ixazomib, now commonly used as a treatment for cancer. Disulfiram has been proposed as another proteasome inhibitor. [10] [11] [12] Epigallocatechin-3-gallate has also been proposed. [13] Marizomib (salinosporamide A) has started clinical trials for multiple myeloma.
Ads
related to: xgeva vs zometa multiple myeloma cancersidekickbird.com has been visited by 100K+ users in the past month